Immunotherapy plus chemo for aggressive sarcoma
Treatments studied
Part of Cancer clinical trials.
This trial compares a combination of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) versus chemotherapy alone for people with aggressive, poorly differentiated sarcomas that have spread or cannot be removed. The goal is to see if adding immunotherapy helps shrink tumors or slow their growth better than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a specific type of sarcoma (like dedifferentiated liposarcoma or undifferentiated pleomorphic sarcoma) that has spread or cannot be surgically removed.
- You have not had chemotherapy with doxorubicin (or similar drugs) before.
- You have not had immunotherapy (like PD-1/PD-L1 inhibitors) before.
- Your heart, kidney, and liver function are within certain limits, and you are able to perform daily activities without major help.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a low dose of a common chemotherapy (liposomal doxorubicin) together with an anti-cancer drug called peposertib. It’s for people with advanced sarcoma that can’t be cured, aiming to find a safe dosing plan and see how well the treatment might work.
This trial tests whether adding chemotherapy before surgery to a combination of immunotherapy (pembrolizumab) and radiation therapy improves outcomes for people with high-risk soft tissue sarcoma (UPS or LPS) in the arm or trunk. It aims to see if this approach can shrink tumors and reduce the chance of cancer returning.
This trial tests a combination of immunotherapy (atezolizumab), chemotherapy (doxorubicin), and radiation before and after surgery for people with high-risk soft tissue sarcoma in the arm, leg, or trunk. The goal is to see if this approach can improve outcomes.
This trial tests whether adding a new drug called DT-7012 to standard chemotherapy (doxorubicin) works better than chemotherapy alone for two types of advanced soft tissue sarcoma. It aims to see if the combination can shrink tumors or slow their growth.
This trial tests a combination of radiation therapy, a lower dose of chemotherapy, and an immunotherapy drug called toripalimab before surgery for a rare type of soft tissue sarcoma called undifferentiated pleomorphic sarcoma (UPS). The aim is to shrink the tumor and improve the chances of successful surgery.
This study tests whether giving radiation, chemotherapy, and immunotherapy together can control high-risk soft tissue sarcoma that is hard to remove or may come back after surgery. It may help by attacking cancer in different ways, including boosting the immune system.
Hear when a new Metastatic Dedifferentiated Liposarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.